Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Forbion Capital Partners. (6/18/24). "Press Release: Forbion Co-leads $190 Million Financing of Marea Therapeutics". Naarden.

Organisations Organisation Forbion Capital Partners (NL)
  Group Forbion (Group)
  Organisation 2 Marea Therapeutics (US)
Products Product MAR001 (anti-ANGPTL4 mAb) (Marea Therapeutics)
  Product 2 venture capital
Person Person Boulanger, Antoine (Forbion 202406 Principal)

> Marea Therapeutics launches with $190 Million in financing to advance the clinical development of a new generation of medicines for cardiometabolic diseases

> Co-Lead Forbion is joined by a broad investor syndicate, including lead investor Sofinnova Investments, Perceptive Xontogeny Venture Fund, venBio, Omega Funds, AlphaWave Global, Surveyor Capital (a Citadel company) and founding investor Third Rock Ventures.

> Lead program, MAR001, is a first-in-class ANGPTL4 inhibitor in Phase 2 clinical development aiming to address the untreated lipid and metabolic drivers of cardiovascular events in high-risk patients

> As part of the financing, Antoine Boulanger, PhD, will join the Board of Directors.

Marea Therapeutics, a clinical-stage biotechnology company developing a new generation of medicines for cardiometabolic diseases, launched today with $190 million in combined Series A and B financing. This financing will fund the company’s MAR001 Phase 2 development plan and further progression of additional pipeline programs.

Marea’s lead program, MAR001, is a monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and preferentially augmenting adipose tissue lipoprotein lipase (LPL) activity, MAR001 aims to lower remnant cholesterol, improve adipose tissue and metabolic function, and reduce cardiovascular events. Remnant cholesterol is carried by triglyceride-rich lipoproteins, is highly atherogenic, and drives cardiovascular events independent of classical risk factors like LDL cholesterol, diabetes or obesity.

“There are currently no targeted therapies to lower remnant cholesterol and improve metabolic function. As an innovative first-in-class program aimed at solving this large unmet medical need, Marea represents our long-term commitment to the space and leverages our deep domain expertise,” said Antoine Boulanger, Ph.D., Principal at Forbion and Marea board member. He added, “we are pleased to collaborate with such a dedicated group of leaders, investors and advisors in order to deliver on the emerging promise of ANGPTL4 to lower remnant cholesterol, improve metabolic health, and ultimately reduce cardiovascular events.”

“Marea aims to transform the way cardiometabolic diseases are treated by leveraging large-scale human genetics and expertise in adipose function and biology to pursue genetically validated targets focusing on central - but unaddressed - drivers of cardiometabolic disease risk,” said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. “This approach could be the next frontier for patients with cardiometabolic disease who remain at very high risk, despite currently available therapies.”

Marea is also advancing a pipeline of additional candidates aimed to address additional untapped nodes driving cardiometabolic disease.


About Forbion

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Boston and Germany. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages €3 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with investments in over 95 companies across 8 funds. Forbion’s record of sourcing, building and guiding life sciences companies has resulted in many breakthrough therapies and valuable exits. Portfolio company successes include NewAmsterdam Pharma (NASDAQ: NAMS), Dyne Therapeutics (Nasdaq: DYN) and Aiolos Bio (acquired by GSK). Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

For more information, please visit:

About Marea

Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development to lower remnant cholesterol in adults with metabolic dysfunction and high risk for cardiovascular disease. Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology. To learn more, please visit and follow us on LinkedIn and X.

For more information, please contact:

Forbion Communications
Head of Communications

Record changed: 2024-07-04


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Forbion (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Consultech GmbH Secure Funding with RnD Grants 650x300px

» top